Citius (CTXR, $2.59) stock drops, on panel recommendation to continue antibiotic trial
On Thursday, Citius Pharmaceutical shares dropped, following news of a panel recommendation that a Phase 3 trial of the company’s antibiotic treatment for catheter-related bloodstream infections should continue.
Investors may have been expecting the trial to stop early instead of continuing as planned, after the drug showed better results compared to typical antibiotic treatment according to a Bloomberg report.
According to Citius, the independent data monitoring panel for the Mino-Lok Phase 3 pivotal superiority trial recommended that the company should continue with the trial as planned. Myron Holubiak, president and chief executive mentioned that this would be the third recommendation by the DMC supporting the continuation of the Mino-Lok trial. He said the outcome indicates that “based on our predefined parameters, it would be possible to achieve our primary endpoint by continuing the trial as planned, and is an encouraging signal when combined with the results of our prior studies."
The panel did not mention any safety concerns.
CTXR's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CTXR turned positive on June 22, 2026. Looking at past instances where CTXR's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 10, 2026. You may want to consider a long position or call options on CTXR as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CTXR advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 47 cases where CTXR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTXR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CTXR broke above its upper Bollinger Band on June 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.260) is normal, around the industry mean (22.889). P/E Ratio (0.000) is within average values for comparable stocks, (37.790). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). CTXR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (1.871) is also within normal values, averaging (434.236).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CTXR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTXR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a pharmaceutical company
Industry Biotechnology
Advertisement